192330-11-3

Basic information

• Product Name: 4-Boc-piperazine-2-carboxylic acid
• Synonyms: 4-BOC-PIPERAZINE-2-(R)-CARBOXYLIC ACID;(4-N-BOC)PIPERAZINE(2R) COOH;(R)-PIPERAZINE-1,3-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER;(R)-4-(TERT-BUTOXYCARBONYL)PIPERAZINE-2-CARBOXYLIC ACID;(R)-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID;(R)-4-BOC-PIPERAZINE-2-CARBOXYLIC ACID;(S)-4-Boc-2-piperazine carboxylic acid;(R)-1-Boc-piperazine-3-carboxylic acid
• CAS NO: 192330-11-3
• Molecular Formula: C₁₀H₁₈N₂O₄
• Molecular Weight: 230.26
• Product Categories: pharmacetical;Piperaizine
• Mol File: 192330-11-3.mol

Chemical Properties

• Melting Point: 231-239 ºC
• Boiling Point: 371.785 °C at 760 mmHg
• Flash Point: 178.649 °C
• Appearance: /
• Density: 1.193 g/cm³
• Vapor Pressure: 1.5E-06mmHg at 25°C
• Refractive Index: 1.495
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.20±0.20(Predicted)
• CAS DataBase Reference: 4-Boc-piperazine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Boc-piperazine-2-carboxylic acid(192330-11-3)
• EPA Substance Registry System: 4-Boc-piperazine-2-carboxylic acid(192330-11-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-43-36
• Safety Statements: 26-36/37/39-36/37
• Hazardous Substances Data: 192330-11-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Boc-piperazine-2-carboxylic acid is used as a synthetic intermediate for the preparation of substituted Azacyles, which are known as TRPM8 modulators. These modulators play a crucial role in targeting the TRPM8 ion channel, which is involved in various physiological processes such as cold and pain sensation, as well as the regulation of body temperature and fluid secretion. By modulating the activity of TRPM8, these compounds have potential applications in the development of therapeutics for conditions like chronic pain, cold hypersensitivity, and bladder dysfunction.

InChI:InChI=1/C10H18N2O4/c1-10(2,3)16-9(15)12-5-4-11-7(6-12)8(13)14/h7,11H,4-6H2,1-3H3,(H,13,14)/t7-/m1/s1

Upstream product

• 74651-77-7 2-(tert-butoxycarbonyloxyimino)-2-phenylacetonitrile 

Downstream Products

• 192330-12-4 2(R)-4-(t-butoxycarbonyl)-1-(4-(4-chlorophenoxy)-benzenesulfonyl)-piperazine-2-carboxylic acid 
• 637027-27-1 1-[4-(4-fluorophenoxy)-3,5-difluorophenyl]sulfonyl-4-boc-piperazine-2-(R)-carboxylic acid 
• 173774-48-6 (R)-piperazine-1,2,4-tricarboxylic acid 1,4-di-tert-butyl ester 

Relevant articles and documents

Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof

The invention relates to compounds of the formula 1: wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt of solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

Metalloproteinase inhibitors and intermediates useful for their preparation

PCT No. PCT/US96/19328 Sec. 371 Date Jun. 29, 1998 Sec. 102(e) Date Jun. 29, 1998 PCT Filed Dec. 5, 1996 PCT Pub. No. WO97/20824 PCT Pub. Date Jun. 12, 1997The invention relates to compounds of formula (1) wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder is carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of formula (1) or a prodrug, salt or solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.

Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

The invention relates to compounds of the formula I STR1 in which Q is a divalent radical having four ring atoms which together with C* and N form a six-membered ring, each of these four ring atoms being unsubstituted or substituted by a suitable substituent and at least one being a heteroatom selected from O, N and S, with the remainder being carbon atoms; and Ar is an aryl or heteroaryl group. The invention further relates to pharmaceutically acceptable prodrugs and pharmaceutically acceptable salts of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases, especially MMPs or TNF-α, by administering a compound of the formula I or a salt or prodrug thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, salts, and prodrugs.